본문으로 건너뛰기
← 뒤로

Multimodal Imaging to Improve Patient Selection and Optimize Treatment Planning and Delivery for Patients Undergoing Reirradiation: A Scoping Review.

리뷰 1/5 보강
Current oncology reports 📖 저널 OA 59.5% 2023: 1/2 OA 2025: 11/19 OA 2026: 12/20 OA 2023~2026 2025 Vol.27(10) p. 1155-1169
Retraction 확인
출처

Beddok A, Rozenblum L, Calugaru V, Feuvret L, Champion L, Eddine CA, Crehange G, El Fakhri G, Buvat I

ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 43.9%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도

📝 환자 설명용 한 줄

[PURPOSE OF REVIEW] Advances in radiation therapy techniques that allow for better normal tissue sparing have made reirradiation (reRT) a more viable option for managing locoregional recurrences in va

이 논문을 인용하기

↓ .bib ↓ .ris
APA Beddok A, Rozenblum L, et al. (2025). Multimodal Imaging to Improve Patient Selection and Optimize Treatment Planning and Delivery for Patients Undergoing Reirradiation: A Scoping Review.. Current oncology reports, 27(10), 1155-1169. https://doi.org/10.1007/s11912-025-01708-9
MLA Beddok A, et al.. "Multimodal Imaging to Improve Patient Selection and Optimize Treatment Planning and Delivery for Patients Undergoing Reirradiation: A Scoping Review.." Current oncology reports, vol. 27, no. 10, 2025, pp. 1155-1169.
PMID 40830323 ↗

Abstract

[PURPOSE OF REVIEW] Advances in radiation therapy techniques that allow for better normal tissue sparing have made reirradiation (reRT) a more viable option for managing locoregional recurrences in various cancers. However, severe toxicity and a high risk of second recurrence persist, emphasizing the need for improved patient selection and treatment planning. This scoping review, registered in the PROSPERO database (CRD42023387364), followed PRISMA guidelines. A thorough search was conducted from 2012 to December 2023 in MEDLINE (via PubMed) and BioMed Central databases, focusing on studies that reported the value of multimodal imaging in enhancing patient selection and optimizing reRT planning. Inclusion criteria targeted studies involving MRI and PET imaging, with exclusions based on relevance, language, and quality.

[RECENT FINDINGS] Of 363 records identified, 29 studies met inclusion criteria. Most focused on high-grade glioma (HGG, 48%), head and neck cancer (HNC, 31%), and pelvic cancer (21%). In HGG, F-FET PET and GdT1w-MRI linked larger, metabolically active volumes with shorter overall survival (OS). Radiomic signatures from pre-reRT PET/MRI, extracted from the planned reRT volume, were associated with post-reRT recurrence, reflecting the prognostic value of intratumoral heterogeneity. Multimodal imaging differentiated disease progression from post-treatment changes, aiding target delineation. Techniques like C-MET PET, F-FET PET, and diffusion-weighted imaging for HGG, as well as F-FDG PET and dynamic contrast imaging for HNC, enhanced target definition and enabled dose-painting. MRI-guided reRT reduced urinary toxicity in prostate cancer through precise treatment adaptation. Multimodal imaging is essential for patient selection, target delineation, and adaptive reRT in recurrent cancers. Further research and standardization are needed to maximize its clinical impact.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (2)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반